Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
0.51Last Year’s EPS
0.48Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: -9.62%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance in the quarter, with significant growth in core areas and strategic expansion. While there are challenges, particularly in China and foreign exchange impacts, the overall outlook remains positive with expectations of continued growth and recovery in key markets.Company Guidance
During Bio-Techne's second quarter of fiscal year 2025, the company reported a 9% organic revenue growth, driven by strong performances in biopharma and protein analysis portfolios. The company's adjusted operating margin increased by 110 basis points sequentially to 30.1%. In terms of geographic performance, sales in the Americas and EMEA grew in low double digits, supported by robust demand from cell therapy customers and automated protein analysis products, which grew over 20%. However, sales in China declined by low single digits, though a return to growth is expected in the upcoming quarter. The GMP reagent business saw a significant 90% revenue increase, with more than 500 customers, including 85 in various clinical trial phases. Bio-Techne's protein sciences segment achieved an 8% organic revenue growth, while the diagnostics and spatial biology segment grew by 12%. The company also highlighted its progress in AI initiatives, launching new designer proteins with enhanced features and expecting a steady cadence of new launches. Adjusted EPS for the quarter was $0.42, with total revenue reaching $297 million. Bio-Techne maintains a strong balance sheet and continues to focus on strategic M&A opportunities while anticipating continued growth and margin expansion in the second half of the fiscal year.Strong Fiscal Quarter Performance
Bio-Techne delivered a strong fiscal quarter, exceeding initial projections with a 9% organic revenue growth driven by biopharma end markets and significant demand for GMP AdHens in protein analytical instrumentation.
Increased Operating Margin
The adjusted operating margin increased by 110 basis points sequentially to 30.1% due to organizational and operational efficiency improvements.
Expansion in EMEA and New Partnerships
The EMEA region grew low double digits, driven by a 20% growth in the automated protein analysis portfolio. New distribution agreements with LeaderLife Sciences and MedSomTec expanded geographic reach.
GMP Reagents Growth
GMV agents' revenue increased over 90% for the quarter, with a trailing twelve-month organic growth of over 40%.
Protein Analysis Growth
Instrument-specific consumables increased high teens, marking eight out of the last nine quarters with double-digit consumable growth. New instrument placements also showed positive growth.
Spatial Biology and Precision Diagnostic Tools Growth
The spatial biology segment delivered 12% organic growth, with the launch of the comet system contributing to mid-teens revenue growth.
Strong Cash Flow and Shareholder Returns
Generated $84.3 million in cash from operations, returned $12.7 million in dividends, and conducted a $75.6 million share stock buyback.
---
TECH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TECH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | $72.46 | $75.16 | +3.73% |
| Oct 30, 2024 | $70.58 | $75.85 | +7.47% |
| Aug 07, 2024 | $78.16 | $70.72 | -9.52% |
| May 01, 2024 | $62.94 | $73.14 | +16.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bio-Techne (TECH) report earnings?
Bio-Techne (TECH) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Bio-Techne (TECH) earnings time?
Bio-Techne (TECH) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TECH EPS forecast?
TECH EPS forecast for the fiscal quarter 2025 (Q3) is 0.51.
---